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Abstract
Background: This study aimed to construct a prediction model to identify subjects with high glycated
hemoglobin (HbA1c) levels by incorporating anthropometric, lifestyle, clinical, and biochemical information in a
large cross-sectional ethnic Chinese population in Taiwan from a health checkup center.
Methods: The prediction model was derived from multivariate logistic regression, and we evaluated the
performance of the model in identifying the cases with high HbA1c levels (> = 7.0%). In total 17,773 participants
(age > = 30 years) were recruited and 323 participants (1.8%) had high HbA1c levels. The study population was
divided randomly into two parts, with 80% as the derivation data and 20% as the validation data.
Results: The point-based clinical model, including age (maximal 8 points), sex (1 point), family history (3 points),
body mass index (2 points), waist circumference (4 points), and systolic blood pressure (3 points) reached an area
under the receiver operating characteristic curve (AUC) of 0.723 (95% confidence interval, 0.677- 0.769) in the
validation data. Adding biochemical measures such as triglycerides and HDL cholesterol improved the prediction
power (AUC, 0.770 [0.723 - 0.817], P = < 0.001 compared with the clinical model). A cutoff point of 7 had a
sensitivity of 0.76 to 0.96 and a specificity of 0.39 to 0.63 for the prediction model.
Conclusions: A prediction model was constructed for the prevalent risk of high HbA1c, which could be useful in
identifying high risk subjects for diabetes among ethnic Chinese in Taiwan.
Background
Poor control of type 2 diabetes, presenting as an ele-
vated glycated hemoglobin (HbA1c) level, is associated
with macro- and micro-vascular complications among
patients with diabetes [1-3]. HbA1c, similar to fasting
and post-challenge glucose levels, is a marker for moni-
toring glucose levels to prevent diabetic complications,
such as retinopathy [4]. Furthermore, a high HbA1c
level in the general population predicts a further risk of
coronary heart disease [5]. Therefore, it is mandatory to
construct a prediction model to identify individuals with
a high HbA1c level in the general population, despite
the low prevalence (1.3%) [6].
A prediction model using anthropometric, lifestyle,
clinical and biochemical measures from routine examina-
tions has been developed to identify high-risk individuals
for diabetes in cross-sectional [7-10] and prospective
cohort studies [11-18]. These models appear to be effec-
tive in identifying people with a high risk of diabetes.
However, the prediction model for a high HbA1c level is
limited [6,19] and there is currently no data available on
ethnic Chinese. In this study, a prediction model was
constructed and its performance tested in detecting pre-
valent but unknown levels of high HbA1c in a large,
cross-sectional ethnic Chinese population who were
recruited from a health checkup program in Taiwan.
Methods
Subjects
This cross-sectional study involved 25,452 adult subjects
who participated in the health checkup program at the
Health Management Center of one tertiary hospital, from
January 2003 to December 2006. The sampling strategy
for the study population, including inclusion and exclu-
sion criteria, is shown in Additional file 1, Figure S1.
After excluding subjects with a history of diabetes with
medication, cardiovascular disease, cancer, missing or
duplicated data, and age less than 30 years, a total of
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study protocol has been described previously [20,21].
Briefly, details of socio-economic status, along with medi-
cal and medication histories were collected by question-
naires, and standardized clinical measure procedures
were undertaken. The protocol was approved by the
hospital’s Institutional Research Board. Standardized
physical examination procedures, such as anthropometric
measures and blood pressure, were also performed
[22,23]. Blood pressure was measured in a resting posi-
tion by trained medical assistants, while body mass index
(BMI) was calculated as weight (in kilograms)/square of
height (in meters), and waist circumference was mea-
sured midline between the low costal margin and super-
ior posterior iliac crest.
Blood Sampling and Analytic Methods
The procedures for blood sampling and analytic meth-
ods have been described in previous studies [22,24].
Briefly, blood samples were collected from each partici-
pant after fasting for at least 12 hours. Serum total cho-
lesterol levels were measured using the CHOD-PAP
method (Boehringer Mannheim, Germany). HDL choles-
terol was measured following precipitation of apolipo-
protein B-containing lipoproteins with phosphotungstic
acid and magnesium ions (Boehringer Mannheim, Ger-
many). Triglyceride concentrations were measured by
the GPO-DAOS method (Wako Co., Japan). The afore-
mentioned lipids were measured using a Hitachi 7450
automated analyzer (Hitachi, Japan). LDL-C concentra-
tions were calculated using the Friedewald formula. CRP
was measured by automated nephelometric immunoas-
say using a Beckman Array instrument (Beckman Array
360 system, Canada). All of the measurements were car-
ried out in a single hospital with a coefficient of varia-
tion of 5%. HbA1c levels were measured by automatic
high-performance liquid chromatography using a
Bio-Rad HbA1c kit (Bio-Rad Diagnostic Group, Her-
cules, CA, USA) in the central laboratory of the hospital.
Standardization using mass spectroscopy and capillary
electrophoresis was used, and prepared mixtures of puri-
fied HbA1c and HbA0 were used as calibrators [25].
With regards to the cutoff level of HbA1c, abnormally
high HbA1c levels were defined as 6.7% according to
the sensitivity and specificity of diabetes diagnosis and
diabetic retinopathy in one cross-sectional study [26]. In
a d d i t i o n ,as t u d yb yt h eU KP r o s p e c t i v eD i a b e t e sS t u d y
Group demonstrated that over 10 years, the mean
HbA1c level in their intensive treatment group was 7.0%
[1]. Moreover, an HbA1 level of 7.3% or greater is con-
sidered the cutoff value for screening diabetes in Pima
Indians [27]. Therefore, we set the threshold for abnor-
mally high HbA1c at 7%.
Statistical analysis
The basic demographic, anthropometric measurements,
lifestyle factors, and biochemical measures were
described according to a high HbA1c concentration,
defined as HbA1c ≥ 7%. The constructed model for
HbA1c ≥ 6.5% was similar so that we reported the find-
ings about HbA1c ≥ 7%. Missing waist circumference
data in the first year (2003) were imputed with the
mean values of waist circumference due to the specific
HbA1c status to improve the power of the prediction
model. The study population was divided randomly into
two parts, with 80% as the derivation data and 20% as
the validation data.
Multivariate logistic models were used to predict the
risk of a high HbA1c level in the derivation data. First,
the Cambridge model [28], including variables of age,
BMI, anti-hypertensive medication, family history, and
smoking status was used to construct the model [6,19].
Second, an additional anthropometric measurement
(waist circumference) and systolic blood pressure were
incorporated into the model. History of hypertension
medication was excluded due to non-significance in the
model. This second prediction model was called the
clinical model. Third, important biochemical indicators,
including C-reactive protein (CRP), HDL cholesterol,
and triglyceride concentrations were added into the
model to construct the full biochemical model [29].
Fasting glucose was not included in the model to pre-
vent over-correction by glucose concentration.
Based on results of the multivariate logistic models
from the derivation data, two strategies for constructing
the prediction model were applied. First, the coefficients
for the prediction model from the derivation data were
used directly, which is a common strategy in the litera-
ture [18,30-32]. By directly calculating the coefficients
and individual variables, the individual risk was derived
in the validation data. We provided the nomogram using
Harrell’s method [33]. Second, a point-based chart was
constructed from the derivation data according to the
strategy suggested by Sullivan and colleagues [34]. This
strategy was as follows: continuous variables were orga-
nized into meaningful categories and the reference values
for each variable were determined. We assigned a 5-year
increase in age as the referent risk, and points associated
with each of the categories of the risk factors were calcu-
lated by comparing with the referent risk. Therefore, an
individual’s risk was constructed from the validation data
by the following formula: Risk = 1/[1 + exp(-bX)] where
bX is the sum of the reference risk and the product of
the 5-year risk constant and the individual points [34].
Performance of the proposed coefficient-based and
point-based prediction models were compared with the
Cambridge model [6,19,28]. The area under the receiver
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pare the discriminatory capability among the models.
A receiver operating characteristic curve is a graph of
sensitivity versus 1-specificity (or false-positive rate) for
various cut-off definitions of a positive diagnostic test
result [35]. Statistical differences in the AUCs were
compared using the method of DeLong et al [36].
Furthermore, the goodness-of-fit for all models was
assessed based on the Hosmer-Lemeshow test [37]. The
global summary statistics included the Brier score [38],
twice the forecast-outcome-covariance (a measure of
how accurately the forecast corresponds to the outcome,
similar to R
2 in linear regression) [39], and discrimina-
tion (c statistic), which is the same as the AUC [40].
The simple points model was compared with other
models using net reclassification improvement (NRI)
and integrated discrimination improvement (IDI) statis-
tics [41]. NRI was based on the reclassification tables
and was calculated from a sum of differences between
the “upward” movement in categories for event subjects
and the “downward” movement of non-event subjects
[41]. The NRI was presented according to the presumed
risk categories of high HbA1c according to quartiles
(0.6%, 1.2%, and 2.6%). The IDI was viewed as the differ-
ence between improvement in average sensitivity and
any potential increase in average “one minus specificity”.
The statistic was a difference in Yates discrimination
slopes between the new and old models [38,42].
All of the statistical tests were two-sided with a type I
error of 0.05, and P values < 0.05 were considered statis-
tically significant. Analyses were performed with SAS
version 9.1 (SAS Institute, Cary, NC), Stata version 9.1
(Stata Corporation, College Station, Texas) and R http://
www.R-project.org.
Results
Basic characteristics
Among the study participants, 323 cases (1.8%) had an
HbA1c level ≥ 7%. Table 1 shows the basic demographic,
clinical, lifestyle, socio-economic status and biochemical
measures of the study participants. Participants with
higher HbA1c levels were likely to be older, male, have a
higher body mass index (BMI), waist circumference, blood
pressure, cholesterol, triglycerides, CRP, and white blood
cell count, and lower HDL cholesterol level. In addition,
participants with higher HbA1c values were likely to take
anti-hypertensive medication, have a higher rate of a posi-
tive family history of diabetes and current smoking status.
The distribution of socio-economic information, such as
martial status and job, was similar between participants
with and without abnormal HbA1c levels. The distribu-
tions of most continuous and categorical variables were
consistent in each gender, and there was no differential
effect.
Constructing the prediction models
The results of the multivariate logistic regression models
are listed in Table 2. Hypertension medication was not
statistically significant and was excluded in further ana-
lyses. Waist circumference and BMI were both asso-
ciated with abnormal HbA1c levels in the clinical
model. Age, family history of diabetes, waist circumfer-
ence, systolic blood pressure, and biochemical measures,
including CRP and triglycerides, were significantly asso-
ciated with higher HbA1c levels. HDL cholesterol was
borderline inversely associated with higher HbA1c.
Regression coefficient-based and point-based predic-
tion models based on the clinical and biochemical mod-
els were developed. A nomogram based on the clinical
and biochemical models was constructed (Figure 1).
Table 3 shows the point-based clinical model to esti-
mate high HbA1c risk using the points system, derived
from the coefficients of the clinical model: age (8 points),
sex (1 point), family history (3 points), BMI (2 points),
waist circumference (4 points), and systolic blood pres-
sure (3 points). This approach allowed for the manual
estimation of the risk of developing a higher HbA1c
level for each individual (Table 3). The waist circumfer-
ence-related point-based biochemical model, additionally
including HDL cholesterol (3 points) and triglycerides
(2 points), is shown in Additional file 1, Table S1.
A cutoff point of 7 had a sensitivity of 0.76 to 0.96 and
a specificity of 0.39 to 0.63 for both clinical and bio-
chemical prediction models.
Performance measures of the prediction model
The performance of the prediction models, including
the Cambridge (Additional file 1, Table S2), coefficient-
based and point-based clinical, and biochemical models
were compared using different measures (Table 4). The
clinical models had a fair discrimination ability with an
AUC of 0.712 (95% confidence interval [CI] 0.664-
0.760), and 0.723 (95% CI, 0.677-0.769) in the coeffi-
cient-based and point-based models, respectively.
Adding biochemical measures improved the prediction
(AUC of 0.773 [95% CI, 0.726-0.821] and 0.770 [95% CI,
0.723-0.817] for the coefficient-based and point-based
models, respectively). Moreover, in the biochemical
models, the AUCs were the highest and the Brier scores
w e r et h el o w e s t ,a n dt h e yw e r el i k e l yt oh a v eas m a l l e r
Hosmer-Lemeshow chi-square and high P values, indi-
cating a good calibration ability for a high HbA1c level.
Figure 2 shows the AUCs of the various prediction
models in the validation data. The Hosmer-Lemeshow
chi-square values indicated a goodness-of-fit for these
prediction models.
The performance ability between the various predic-
tion models was tested using NRI and IDI statistics
(Table 5). The clinical coefficient-based model was
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HbA1c concentration
HbA1c < 7%
n = 17450
HbA1c> = 7%
n = 323
Mean SD Mean SD P value
Age, year 51.0 10.9 56.6 10.2 < .0001
BMI, kg/m
2 23.8 3.2 25.8 3.7 < .0001
Waist, cm 83.5 9.1 89.6 9.9 < .0001
Systolic BP, mmHg 122.6 16.0 131.6 16.1 < .0001
Diastolic BP, mmHg 73.1 10.5 77.5 10.2 < .0001
Fasting glucose, mg/dL 90.6 10.2 172.0 54.7 < .0001
Postprandial glucose, mg/dL 117.8 48.1 167.7 99.1 < .0001
Total cholesterol, mg/dL 203.7 36.8 220.7 47.3 < .0001
Triglyceride, mg/dL 119.1 75.1 193.0 151.9 < .0001
HDL-cholesterol, mg/dL 44.7 44.1 40.3 8.9 < .0001
LDL-cholesterol, mg/dL 119.6 32.5 134.8 43.5 < .0001
CRP, mg/dL 0.16 0.40 0.31 0.66 < .0001
Uric acid, mg/dL 6.05 1.53 6.03 1.55 0.77
White blood cells 5.43 1.49 6.30 1.76 < .0001
HbA1c, % 5.42 0.37 8.86 1.98 < .0001
%%
Gender women 44.9 31.6 < .0001
men 55.2 68.4
BMI group < .0001
BMI < 25 67.4 43.0
25~30 29.1 45.2
BMI > = 30 3.5 11.8
Medication history
Hypertension 12.7 19.2 0.001
Diuretics usage 1.9 4.3 0.001
Lipid lowering 3.2 3.7 0.59
Family history of diabetes < .0001
None 71.3 61.3
Second relatives 5.4 4.0
First relatives 23.3 34.7
Current smoking Yes 13.9 20.7 0.0004
Alcohol drinking Yes 55.6 50.2 0.05
Martial status Unmarried 11.5 9.5 0.55
Married 87.7 89.6
Separate 0.3 0.6
Unknown 0.5 0.3
Job Manual work 5.4 5.3 0.23
Business 24.0 21.7
Government, Teacher 21.3 17.3
Housework 10.1 12.4
No job 4.6 6.5
Service 5.8 5.6
Student 0.4 0.0
Other job 28.6 31.3
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biochemical models outperformed the Cambridge mod-
els due to a significant increase in IDI and NRI values
(Set 2). The biochemical coefficient-based model had a
better performance than the clinical coefficient-based
clinical model by NRI value (Set 3). In addition, the
clinical point-based model and clinical coefficient-based
model had similar performance measures (Set 4). Finally,
the biochemical coefficient-based model outperformed
the biochemical point-based model (Set 5), and the clin-
ical and biochemical point-based models had a similar
performance (Set 6). The sensitivity, specificity and cut-
off values for the clinical and biochemical models were
listed in Additional file 1, Table S3. Our findings sup-
port that the clinical and biochemical point-based mod-
els were excellent models for identifying individuals
with a high HbA1c value.
Discussion
This study confirms and extends the results of a pre-
vious study [9] that showed significantly associated risk
factors for a high HbA1c concentration in an adult
population. Coefficient-based and point-based prediction
models for clinical practice were constructed. The bio-
chemical model incorporated several clinical and life-
style risk factors, as well as biochemical measures, in
order to provide a feasible and practical tool for detect-
ing high HbA1c levels. The availability of simple clinical
tools to predict the future risk of disease, such as those
for predicting coronary heart disease [43-45], can
improve predicting the risk of high HbA1c, identify
high-risk populations, and enhance preventive strategies.
Thomas and colleagues investigated 7452 45-year-old
British adults to compare the predictive power of the
Cambridge risk score and body mass index for elevated
H b A 1 cl e v e l s[ 1 9 ] .T h e yf o u n dt h a tt h eC a m b r i d g e
prediction model and body mass index had a similar
identifying power for diabetes risk. Park et al. collected
clinical data from 6567 adults in the European Prospec-
tive Investigation of Cancer-Norfolk cohort and showed
that the Cambridge model performed well in predicting
high HbA1c levels{Park, 2002 [6]}. In several other
cross-sectional studies conducted in the US and Europe,
prediction models based on clinical information and life-
style-related factors have appeared to be useful in
screening and identifying undiagnosed diabetes cases
and high HbA1c levels among various populations
[10,28,46,47].
The Cambridge risk model, including age, sex, steroid
or antihypertensive medication, smoking, family history,
and body mass index, has a specificity of 78% and a sensi-
tivity of 51% to screen cases with HbA1c > = 7.0%[6]. In
another screening project for a high HbAc1 level defined
as 7.0%, the Cambridge risk model was proven to be a
good performance measure [19]. Although different cri-
teria for defining high HbA1c levels for identifying
undiagnosed diabetes and screening high risk cases,
including 6.5% [9], 7.0% [6] and 7.5% [27], are available,
we focused on a cutoff point of 7.0% in this study.
Based on these observations, this study provided a bet-
ter prediction model than the Cambridge model for pre-
dicting a high HbA1c level among ethnic Chinese. We
showed that some biochemical measures, especially
components related to metabolic syndrome and inflam-
mation such as triglycerides, low HDL cholesterol, and
CRP, provide additional information for predicting a
high HbA1c level. Aside from fasting glucose and MI,
metabolic variables such as high triglycerides and low
HDL were found to be strong predictors of type 2 dia-
betes. These variables also included risk functions devel-
oped in other populations [10,48] and were related to a
h i g hH b A 1 cl e v e l .O u rs t u d yd i dn o ts u p p o r tar o l ef o r
Table 2 Regression coefficients, standard errors and significant levels of various covariates in the two prediction
models among the derivation data
Clinical Biochemical
Variable Estimated parameter SEM P Estimated parameter SEM P
Intercept -12.906 0.775 < .0001 -11.668 0.922 < .0001
Sex, men vs. women 0.351 0.152 0.021 0.174 0.160 0.28
Age, +1 year 0.042 0.006 < .0001 0.043 0.006 < .0001
BMI, +1 kg/m
2 0.076 0.031 0.014
Waist, +1 cm 0.024 0.012 0.046 0.036 0.008 < .0001
Family history 0.710 0.138 < .0001 0.724 0.140 < .0001
Smoking history 0.433 0.173 0.012 0.209 0.178 0.24
Systolic blood pressure, +1 mmHg 0.017 0.004 < .0001 0.016 0.004 0.0003
CRP, +1 mg/dL 0.229 0.079 0.004
HDL, +1 mg/dL -0.018 0.008 0.029
Triglyceride, +1 mg/dL 0.004 0.001 < .0001
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multivariate model.
In our clinical model, a family history of diabetes and
systolic blood pressure had significant predictive power
for the risk of high HbA1c, and the results imply that
these two factors, aside from BMI and waist circumfer-
ence, should be checked to screen for high HbA1c. Our
point-based model clearly showed that family history,
BMI, waist circumference, and systolic blood pressure
synergistically added to the risk of high HbA1c.
T h ec h o i c eo fo p t i m a lt h r e s h o l df o rd e f i n i n gah i g h
HbA1c level is still inconclusive [26,27,49]. Engelgau
and colleagues collected information on diabetic retino-
pathy and provided the diagnostic threshold of HbA1c
as 6.7%. However, Hanson et al. used a similar strategy
but argued that the best cutoff value should be 7.8%.
We used 7.0% as the threshold following previous pre-
diction model results [6,19] and because micro-vascular
complications increase appreciably when HbA1c > 7.0%.
Figure 1 Nomogram to calculate the probability of high
glycated hemoglobin (HbA1c > 7%) using the clinical (upper)
and biochemical (lower) models. In the clinical models, sex
(women as 0, men as 1), age, body mass index (BMI), waist
circumference (WC), family history of diabetes (FHX), smoking, and
systolic blood pressure (SBP) are calculated by reading from the
point scale. In the biochemical model, only triglyceride (TG) is
calculated. The total point score is then translated into probability
of high HbA1c using the bottom scales, including total points and
probability. For example, the probability of high HbA1c with a total
point score of 170 is then 0.06, according to the two bottom lines.
The participants can be classified according to the absolute
probabilities accordingly.
Table 3 Simple points system according to the clinical
model and the simple points clinical model and absolute
risk function for High HbA1c (> = 7%)
Risk factor Category Point Points
total
Absolute
Risk
Age, yr 30-39 0 0 0.002
40-49 2 1 0.002
50-59 4 2 0.002
60-69 6 3 0.003
> = 70 8 4 0.004
Sex Women 0 5 0.004
Men 1 6 0.005
Family history No 0 7 0.007
Yes 3 8 0.008
Current smoker No 0 9 0.01
Yes 2 10 0.013
BMI, kg/m2 < 21.1 0 11 0.015
21.1-22.7 0 12 0.019
22.8-24.3 1 13 0.023
24.4-26.2 1 14 0.029
> = 26.3 2 15 0.035
Waist circumference, cm <77 0 16 0.043
77-82.9 0 17 0.053
83-83.9 1 18 0.064
84-89.9 1 19 0.078
> = 90 2 20 0.094
systolic blood pressure,
mmHg
<109 0 21 0.114
109-117.9 0
118-125.9 1
126-134.9 2
> = 135 3
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mented easily, and we provide the nomogram for the
coefficient-based models. However, calculations are
still necessary for the absolute risk probability. There-
fore, the point-based models, although with slightly
poorer performance than the coefficient-based models,
are likely to be implemented. Manual calculation of an
individual’s risk by summing the points in the point-
based models is feasible, such that health professionals
can use it in clinical practice. The point-based model
using clinical measures may have a useful role in stra-
tifying a population so that those at the highest risk
are offered further testing and intervention. A high-
risk approach for primary prevention on the risk of
diabetes is recommended [50] and the prediction
model may be a feasible tool. In addition, multifactor-
ial treatment on risk factors, including weight control,
lipids, blood pressure, and glucose level lowering, in
patients with type 2 diabetes is a difficult task [51],
especially for patients with pre-existing cardiovascular
diseases [52]. A high HbA1c level in patients indicates
poor glycemic control, so aggressive intervention is
necessary for patients with high HbA1c.
To the best of our knowledge, this is the first study on
a prediction model specifically developed for the risk of
high HbA1c levels among ethnic Chinese. Because of the
large sample size, estimates from our prediction models
are stable as demonstrated by the internal validation
study. Furthermore, the standardization and central
laboratory mean the measurements are consistent
throughout the study period. The homogeneous study
participants provide a reliable estimate for the prediction
model coefficients. We consider that these prediction
models may be suitable for screening and identifying
those at high risk of type 2 diabetes in the Asia-Pacific
region.
This study had several limitations. First, the prevalent
rate of high HbA1c levels was relatively low (1.8%) so
that the predicted risk probability among the general
population seems negligible. This low risk, however,
may be underestimated. In fact, only 1.3% of partici-
pants had high HbA1c levels in the study conducted by
Park et al. [6]. Therefore, identifying the high-risk popu-
lation using the prediction model will be a useful tool
for further prevention of diabetic complications. Second,
the cross-sectional study design made causation difficult.
Some anthropometric and lifestyle factors might have
been influenced after the onset of diabetes. Our strategy
to exclude existing diabetes cases was meant to reduce
this reverse causation to as minimal as possible. Finally,
we didn’t include fasting plasma glucose in the bio-
chemical model due to its high collinearity with HbA1c.
In addition, the biochemical model was limited to the
population who provided blood samples.
In conclusion, point-based prediction models were
constructed to predict the prevalence of high HbA1c
levels among ethnic Chinese. These simple clinical tools
should help identify high-risk populations and improve
prevention and treatment strategies for type 2 diabetes.
Table 4 Summary statistics for different prediction models based on covariates in the Cambridge, clinical, and
biochemical model algorithms on the validation data
Area under ROC
curve
Brier
score*
2*Forecast Outcome
Covariance
Hosmer
Lemeshow
chi-square**
Hosmer Lemeshow P
value**
Cambridge 0.691 0.0219 0.0004 14.6 0.07
Clinical, coefficient-based 0.712 0.0217 0.0007 12.8 0.12
Clinical, points-based 0.723 0.0220 0.0003 18.7 0.03
Biochemical, coefficient-
based
0.773 0.0213 0.0013 8.8 0.36
Biochemical, points-based 0.770 0.0219 0.0003 3.8 0.87
*A low Brier score indicated a goodness-of-fit. ** Low Hosmer-Lemeshow chi-square and high P values indicated a goodness-of-fit
A higher area under the ROC area as well as 2*Forecast-outcome-covariance represented better performance. A lower Hosmer-Lemeshow chi-square value
represented a goodness-of-fit model.
Figure 2 Areas under the ROC curves for the three prediction
models in the validation data.
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